2025-11-23 - Analysis Report
Okay, here's an analysis of Albemarle Corp (ALB) based on the data you provided. I'll present the analysis in English and include simple numbers and analysis as requested.

## Albemarle Corp (ALB) Analysis

**0) Executive Summary**

Albemarle Corp. is a specialty chemicals company with a focus on lithium, bromine specialties, and catalysts. Currently, the stock is showing mixed signals. While recent news suggests a potential rebound and analysts are cautiously optimistic, past performance lags behind the S&P 500 and recent earnings/financial data raise concerns. The stock appears to be volatile and carries significant risk.

**1) Performance vs. S&P 500 (VOO)**

*   **ALB Cumulative Return:** 12.76%
*   **VOO Cumulative Return:** 94.64%
*   **Absolute Divergence:** -87.3%
*   **Relative Divergence:** 10.6 (on a scale of min/max historical divergence)

**Analysis:** ALB has significantly underperformed the S&P 500. The -87.3% absolute divergence indicates a large performance gap. The relative divergence of 10.6 suggests that, compared to its historical range of performance differences with the S&P 500, ALB is currently positioned near the bottom end of that range.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha    | Beta   | Cap(B) |
|------------|----------|-------|----------|--------|--------|
| 2015-2017  | 85.0%    | 68.0% | 57.0%    | 0.0    | 15.1   |
| 2016-2018  | 9.0%     | 68.0% | -6.0%    | 0.0    | 9.1    |
| 2017-2019  | -44.0%   | 73.9% | -66.0%   | 0.1    | 8.6    |
| 2018-2020  | 44.0%    | 79.4% | 20.0%    | 0.2    | 17.4   |
| 2019-2021  | 149.0%   | 79.4% | 103.0%   | -0.1   | 27.5   |
| 2020-2022  | 148.0%   | 79.9% | 149.0%   | 0.5    | 25.5   |
| 2021-2023  | -26.0%   | 81.9% | -27.0%   | 0.5    | 17.0   |
| 2022-2024  | -152.0%  | 81.9% | -172.0%  | 0.3    | 10.1   |
| 2023-2025  | -209.0%  | 81.9% | -268.0%  | -1.0   | 13.8   |

**Analysis:**

*   **CAGR:** Fluctuates wildly, indicating high volatility. Recent periods show significant negative growth.
*   **MDD:** Consistently high Maximum Drawdown values indicate significant risk of loss.
*   **Alpha:** Recent Alpha figures are very negative, suggesting substantial underperformance relative to a benchmark.
*   **Beta:** Beta values are generally low, but have been fluctuating recently, suggesting the stock's correlation with the market is unstable.
*   **Cap:** The market capitalization has been fluctuating, suggesting that investors' interest in the company is volatile.

**2) Recent Price Action**

*   **Current Price:** $116.82
*   **Previous Close:** $116.42
*   **Change:** +0.34
*   **5-Day Moving Average:** 119.60
*   **20-Day Moving Average:** 105.24
*   **60-Day Moving Average:** 92.43

**Analysis:** The current price is slightly above the previous close, indicating a small positive movement. The 5-day moving average is above the current price, while the 20-day and 60-day moving averages are below, suggesting a potential short-term correction after a recent uptrend.

**3) Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 70.56 (Overbought)
*   **PPO:** 1.09
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (10 shares - Very Safe - MRI:0.90)
*   **Delta (20-Day Relative Divergence Change):** 5.4 (+), indicates a short-term upward trend.
*   **Expected Return:** 194.1% (Long-term, vs. S&P 500)

**Analysis:** The MRI suggests a medium level of investment risk. The RSI indicates the stock is currently overbought, which could precede a price correction. The PPO indicates positive momentum. The hybrid signal suggests a buy recommendation, although this contrasts with the high RSI. The positive change in relative divergence over the past 20 days supports the recent price increase. The very high expected return suggests significant potential upside over the long term, but this needs to be balanced against the risks identified elsewhere. The small positive change in price from the previous close might reflect underlying volatility or a potential shift in market sentiment.

**4) Recent News & Significant Events**

*   **Positive:**
    *   Albemarle Stock Rises After Big Pullback (Barrons.com)
    *   Is Most-Watched Stock Albemarle Corporation (ALB) Worth Betting on Now? (Zacks)
    *   Albemarle Rallies 26% in a Month (Zacks)
    *   Analysts Tout 3 Rare Earth Stocks; Lithium Stocks Stay Hot As AI Boosts Demand (Investor's Business Daily)
*   **Neutral/Negative:**
    *   Top Premarket Decliners (MT Newswires)
    *   How Recent Developments Are Rewriting the Story for Albemarle Stock (Simply Wall St.)

**Analysis:** Recent news is mixed. There are positive headlines highlighting a rebound and potential value. However, other articles point to volatility and a possible rewriting of the Albemarle story, suggesting uncertainty.

**4-2) Analyst Opinions**

*   **Consensus:** Hold
*   **Mean Rating:** 2.65 (~Hold)
*   **Number of Opinions:** 23
*   **Target Price:**
    *   Average: $103.01
    *   High: $200.00
    *   Low: $58.00

**Analysis:** Analyst consensus is a "Hold" with a wide range of target prices, indicating uncertainty about the stock's future performance. The average target price is *below* the current price, suggesting potential downside risk.

**5) Recent Earnings Analysis**

| 날짜       | EPS    | 매출     |
|------------|--------|----------|
| 2025-11-05 | -1.72  | 1.31 B$  |
| 2025-08-04 | -0.16  | 1.33 B$  |
| 2025-04-30 | 0      | 1.08 B$  |
| 2024-11-06 | -9.45  | 1.35 B$  |
| 2025-11-05 | -9.45  | 1.35 B$  |

**Analysis:** The recent earnings data is concerning. EPS (Earnings Per Share) figures are negative for the last several quarters, indicating unprofitability. While revenue has been relatively stable, the negative EPS raises serious questions about the company's operational efficiency and cost management.

**6) Financial Information**

Revenue and Profitability:

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-09-30 | $1.31B    | 8.99%         |
| 2025-06-30 | $1.33B    | 14.80%        |
| 2025-03-31 | $1.08B    | 14.51%        |
| 2024-12-31 | $1.23B    | 11.22%        |
| 2024-09-30 | $1.35B    | -7.68%        |

Capital and Profitability:

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-09-30 | $10.00B   | -1.61%    |
| 2025-06-30 | $10.24B   | 0.22%     |
| 2025-03-31 | $10.03B   | 0.41%     |
| 2024-12-31 | $9.96B    | 0.76%     |
| 2024-09-30 | $10.24B   | -10.44%   |

**Analysis:**

*   **Revenue & Profit Margin:** While revenue has been fairly consistent, the profit margin has fluctuated significantly. The negative profit margin in 2024-09-30 is a red flag. Recent margins are positive but still not consistently high.
*   **Equity & ROE:** Equity is relatively stable. However, ROE (Return on Equity) is generally low and negative for the most recent quarter, indicating poor profitability relative to shareholders' equity.

**7) Overall Conclusion**

Albemarle (ALB) presents a mixed investment picture.

*   **Positives:** Recent positive price momentum, potential long-term upside (as indicated by the high expected return), and some favorable news headlines suggest a potential for recovery. The Hybrid Signal also recommends a buy.
*   **Negatives:** Significant underperformance compared to the S&P 500, high volatility (as evidenced by the MDD and fluctuating CAGR), recent negative earnings and low/negative ROE, and analyst consensus of "Hold" with target prices near or below the current price raise serious concerns. The overbought RSI also suggests a potential short-term pullback.
* **Recent positive changes:** Recent increase in price and related increase in relative divergence shows a short-term increase.

**Recommendation:**  Due to the high risk and conflicting signals, a cautious approach is warranted. This stock may be suitable for investors with a high-risk tolerance and a long-term investment horizon, but thorough due diligence and careful monitoring are essential. It is *not* a suitable investment for risk-averse investors. Consider diversifying your portfolio and consulting with a financial advisor before making any investment decisions.
